Last week (March 14 to March 18), A-Shares experienced a roller coaster market. Under the deep correction of concept shares in the superposition of military conflicts between Russia and Ukraine, the volatility of A-Shares increased, and the number of new shares broken on the first day also increased.
Of the 11 new shares listed last week, 6 broke on the first day, accounting for 55%; Six new shares fell below the issue price on the first day of a week, also setting the highest number of new shares broken on the first day of this year. It is worth noting that the trend of Shanghai and Shenzhen fluctuated more in 2022. Since this year, 69 new shares of A-Shares have been listed, of which 13 broke on the first day, accounting for 19%.
According to the IPO arrangement, six new shares were subscribed this week, including two on the gem and four on the science and innovation board.
\u3000\u3000 0 7
last week, six new shares broke on the first day
Last week, a total of 11 new shares were listed, and 6 broke on the first day, accounting for 55%.
On the first day of last week, silinger broke the new shares with the largest decline. Silinger is mainly engaged in embedded intelligent instrument modules and other industrial automation detection products. It landed on the science and Innovation Board on March 14, raising a total of 1.094 billion yuan, with an issue price of 65.65 yuan, and an issue P / E ratio of 75.69 times, 34.75 times higher than the industry P / E ratio. On March 14, silinjie closed at 50.11 yuan, down 23.67% from the issue price. If calculated by 500 shares in the first signing, the loss on the first day reached 7770 yuan.
Silinger fell 23.67% on the first day, the third highest decline in the first day of new shares listed this year. This year, the largest decline in new shares on the first day of listing was Aojie technology, which fell 33.75% on the first day. Followed by Maiwei biology, which fell 29.6% on the first day.
The new shares of jusailong, which also landed on the gem on March 3 and 14, rose sharply on the first day. Juselon is a high-tech enterprise specializing in the R & D, production and sales of modified plastics. Its main products include modified general plastics, modified engineering plastics, modified special engineering plastics and other polymer materials, and are widely used in household appliances, automotive industry, electronic communication, medical supplies and other fields. Its main customers include Midea Group Co.Ltd(000333) , Zhejiang Supor Co.Ltd(002032) , Hisense Group, Galanz Group, Dongfeng Group Toyota group, Pulian technology and other well-known enterprises.
The issuing price of jusailong is 30 yuan, and the issuing P / E ratio is 19.13 times, which is 25.55 times lower than that of the industry. As of the closing, jusailong closed at 77.3 yuan, up 157.67% compared with the issue price. If it is calculated based on 500 shares in the first signing, it can make a profit of 236500 yuan on the first day.
Six new shares fell below the issue price on the first day of listing in a single week, also the largest number of new shares broken on the first day of this year.
Since this year, 13 A-shares have broken on the first day of listing; According to monthly statistics, 6 new shares were issued in January, 1 in February and 6 since March.
With the depth adjustment of a shares, as of the closing on March 19, 28 of the 69 new shares listed this year have broken, accounting for 41%. The deepest decline is still Aojie technology, with a decline of 55.17% since its listing.
In terms of the increase list, among the new shares listed this year, Hefu China still has the highest cumulative increase. After listing, Hefu China once had 12 boards, with a cumulative increase of more than 425.3%, and Hefu China is also the new share with the largest number of boards this year.
\u3000\u3000 02
rna diagnosis first strand
According to the current arrangement, if there is no change (from March 21 to March 25), a total of 6 new shares are applied for, including 2 on the gem and 4 on the science and innovation board.
Rendu biology, which applied for purchase on Monday, has announced its offering price. Rendu biology’s issuing price is 72.65 yuan, and the issuing P / E ratio is 54.54 times, while the industry’s average dynamic P / E ratio in the last month is 29.01 times.
Rendu biology, which has become the “first share of RNA diagnosis”, is one of the first batch of life science enterprises in China to focus on RNA thermostatic amplification technology and products. The IPO raised 727 million yuan, which will be used for “research and development project of industrialization of precision diagnostic reagents and intelligent devices” and “marketing network construction project”.
Rongchang biology, which is expected to raise 4.151 billion yuan, is the enterprise with the highest amount of new shares this week. Founded in 2008, Rongchang biology has built three core technology platforms with independent intellectual property rights: antibody and fusion protein platform, antibody drug conjugate (ADC) platform and bifunctional antibody platform. Its products cover the fields of autoimmunity, tumor, ophthalmology and other major diseases. Its core products include tetasip (rc18), vidicizumab (rc48) and rc28, of which the first two new drug products have been commercialized.
In addition, Zhongfu Shenying, the pioneer of China’s 1000 ton carbon fiber, applied online on March 24. Zhongfu Shenying is a high-tech enterprise engaged in carbon fiber R & D, production and sales under China Building Materials Group Citic Securities Company Limited(600030) pointed out that in 2012, Zhongfu Shenying took the lead in realizing the industrialization of dry jet wet spinning technology in China, and systematically mastered carbon fiber T700, T800 kiloton technology and T1000 hundred ton technology. In 2020, the company’s carbon fiber output / sales volume was 3777 / 3625 tons, accounting for 20.98% / 7.43% of China’s total carbon fiber output / sales volume, ranking second in China.
[new calendar]
March 21
Ren bio (688193) is a life science enterprise focusing on RNA molecular diagnostic technology and products. It is engaged in the integration of RNA molecular diagnostic reagents and equipment based on RNA real-time fluorescence constant temperature amplification technology (SAT), covering reproductive tract, suction channel, hepatitis B detection and other fields.
March 22
Rongchang Biology (688331) is an innovative biopharmaceutical enterprise with a global vision. After more than ten years of technology and industry experience accumulation, Rongchang biology has built three core technology platforms with independent intellectual property rights: antibody and fusion protein platform, antibody drug conjugate (ADC) platform and bifunctional antibody platform. Its products cover the fields of autoimmunity, tumor, ophthalmology and other major diseases. Its core products include tetasip (rc18), vidicizumab (rc48) and rc28, of which the first two new drug products have been commercialized.
23 March
Tianyi medical (301097) is a high-tech enterprise mainly engaged in the R & D, production and sales of medical devices such as medical polymer consumables in the field of blood purification and ward nursing. It is one of the earliest enterprises in China to focus on this field. Its main products include extracorporeal circulation blood circuit of blood purification device, disposable arteriovenous puncture device, disposable integrated oxygen suction tube, feeder and liquid feeding tube, etc.
changguanghuaxin (688048) focuses on the semiconductor laser industry. Its core products are semiconductor laser chips, “vertical extension” to downstream devices, modules and direct semiconductor lasers, “horizontal expansion” to VCSEL chips, optical communication chips and other semiconductor laser chips. In 2020, the company’s “fulcrum” product high-power semiconductor laser chip ranked first in the Chinese market.
March 24
Zhongfu Shenying (688295) is a national high-tech enterprise specializing in the R & D, production and sales of carbon fiber. The main products sold abroad are carbon fiber. Through years of independent research and development, we have mastered the core technology of the whole process of carbon fiber production, took the lead in breaking through the industrial manufacturing technology of thousand ton carbon fiber precursor dry jet wet spinning in China, and built China’s first thousand ton dry jet wet spinning carbon fiber industrial production line.
March 25
minglida (301268) specializes in the design, R & D, production and sales of precision structural parts and molds. With product R & D, mold design and process design and innovation as the core and based on precision die casting, precision injection molding, profile processing and metal stamping technology, it provides multi-type and one-stop precision structural parts products for high-quality customers at home and abroad.
